
ACCU-BREAK Pharmaceuticals develops bio-equivalent products and licenses tablet technologies for precise dosing.
ACCU-BREAK Pharmaceuticals develops and licenses innovative tablet technologies for precise dosing in pharmaceuticals. Their flagship ACCU-BREAK™ technology allows tablets to be divided by hand into accurate smaller doses, enabling patients to adjust their medication intake. This technology is applicable to single drug products, combination drugs, standard and controlled release formulations, and incompatible drugs in both human and veterinary medicine.
The company's focus on dose flexibility has set a new standard in the pharmaceutical industry. ACCU-BREAK's technologies have wide-ranging applications, from improving patient compliance to potentially reducing medication costs. Their innovative approach to tablet design has positioned them as a significant player in the advancement of personalized medicine and patient-centric drug delivery systems.

Wilmington Pharmaceuticals

Aprecia Pharmaceuticals
aprecia.com

Accera

Actinobac Biomed

NovaDel Pharma

G2B Pharma

Fidelis Pharmaceuticals
fidelisrx.com

BioQ Pharma
bioqpharma.com

Spes Pharmaceuticals
spespharma.com

Aquavit Pharmaceuticals
aquavitpharma.com

Axikin Pharmaceuticals

Quark Pharmaceuticals

Accuitis
accuitis.com

Handa Pharmaceuticals
handapharma.com

Confluence Pharmaceuticals
Companies similar to Accu-Break Pharmaceuticals include Wilmington Pharmaceuticals, Aprecia Pharmaceuticals, Accera and Actinobac Biomed.
Accu-Break Pharmaceuticals was founded in 2001.
Accu-Break Pharmaceuticals' headquarters is located in Hollywood, FL, US.
Accu-Break Pharmaceuticals' most recent funding round was for $1M (USD) in May 2013.
As of May 21, 2013, Accu-Break Pharmaceuticals has raised a total of $6.7M (USD).
Accu-Break Pharmaceuticals has 7 employees as of Feb 5, 2024.